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Increased VLDL in nephrotic patients results from a decreased catab-
olism while increased LDL results from increased synthesis. Increased
very low density lipoprotein (VLDL) in nephrotic patients results from a
decreased catabolism while increased low density lipoprotein (LDL)
results from increased synthesis. Hyperlipidemia is a hallmark of ne-
phrotic syndrome that has been associated with increased risk for ischemic
heart disease as well as a loss of renal function in these patients. The
hyperlipidemia usually is characterized by increased cholesterol levels,
although hypertriglyceridemia may be present as well. The factors that
determine the phenotype of nephrotic dyslipidemia are not understood,
nor has the primary stimulus for nephrotic hyperlipidemia been identified.
One hypothesis is that nephrotic hyperlipidemia is the result of a
coordinate increase in synthesis of proteins by the liver. To address these
issues we simultaneously measured the in vivo rate of VLDL apolipopro-
tein B100 (apo B100) secretion, LDL apo B100 synthesis and albumin
synthesis in patients with a nephrotic syndrome (N 5 8) and compared
them with a control group (N 5 7) using a primed/continuous infusion of
the stable isotope L-[1-13C] valine for six hours. Kinetic data were
analyzed by multicompartmental analysis. Patients studied had combined
hyperlipidemia as reflected by an significant increase in both VLDL and
LDL apo B100 pool sizes. In contrast, the albumin pool size was
significantly decreased. VLDL apo B100 levels were primarily increased as
a consequence of a decrease in fractional catabolic rate (FCR) rather than
from an increase in the absolute synthesis rate (ASR). Both VLDL apo
B100 and triglycerides were inversely related to the fractional catabolism
(FCR) of VLDL apo B100 (r2 5 0.708; P 5 0.0088) while neither had any
relationship to the ASR of VLDL apo B100. In contrast to VLDL,
increased LDL apo B100 was not a consequence of decreased catabolism.
The LDL apo B100 ASR was significantly increased (P 5 0.001) in the
nephrotic patients compared to controls. Low density lipoprotein apo
B100 ASR was greater than that of VLDL apo B100 in some patients,
suggesting that LDL in these patients was not only derived from VLDL
delipidation, but also by an alternative secretory pathway. There was no
clear relationship between the ASR of VLDL apo B100 and the ASR of
albumin within the current study population. Our data indicate that
increased VLDL in nephrotic patients results from a decreased catabo-
lism, while increased LDL results from increased synthesis.
Hyperlipidemia is one hallmark of the nephrotic syndrome
(NS) [1]. Hyperlipidemia in the nephrotic syndrome has been
proposed to result from increased synthesis and decreased catab-
olism of lipoproteins [2–5], although the relative contribution of
each has not been quantitated. The mechanism of hyperlipidemia
is of clinical significance, since hyperlipidemia has been impli-
cated in increased cardiovascular risk and in progression of renal
injury in nephrotic patients [6–8]. Although an increase in total
plasma cholesterol is the most common abnormality, plasma
triglyceride (TG) levels are also increased in patients with more
severe proteinuria [4, 9, 10], but this increase is not invariably
present. It is not known why some patients with the nephrotic
syndrome develop increased TG levels while others do not.
While some investigators have reported an increased rate of
very low density lipoprotein/low density lipoprotein (VLDL/LDL)
secretion, others have not been able to confirm this finding. This
could be due to differences in methodology or to differences in
the patient population studied. Direct measurement of VLDL
catabolism using 125I labeled lipoproteins is complicated by the
fact that VLDL contains several apolipoproteins and more than
one may be labeled. Of greater concern is that most studies
employing iodination of proteins use oxidizing reagents that might
modify lipids and may lead to different processing (such as
scavenger receptor) so that they are processed differently than
native lipoproteins. We avoided these potential artifacts by di-
rectly measuring synthesis and secretion of apolipoprotein B100
(apo B100) in nephrotic patients using stable isotopes. Although
stable isotope measurements require extensive protein isolation
procedures, complex multicompartmental modeling and specific
equipment, no radiation is involved and this method has been
proven to be a feasible approach to measure apo B metabolism [5,
11, 12].
Synthesis of a group of proteins, including albumin, is increased
proportionally in the nephrotic syndrome in experimental animals
[13–15] and in humans [16–18], leading to the hypothesis by
Marsh and Sparks [19] that hyperlipidemia might be a result of a
coordinated increase in synthesis of albumin and other proteins by
the liver, including lipoproteins. In addition, Davis et al [20]
suggested that low albumin states might exert an effect on hepatic
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synthesis of apo B100 by less direct means, specifically by increas-
ing the availability of free fatty acids.
In the present study, synthesis of apo B100 in VLDL and LDL
was therefore measured directly and simultaneously with that of
albumin synthesis in patients with nephrotic syndrome with a wide
range of proteinuria, albumin and hyperlipidemia, using endoge-
nous labeling with infused 13C valine as a precursor.
METHODS
Subjects
Eight patients (6 males, 2 females) were recruited for the study
from the renal division of the University Hospital Utrecht. The
mean age was 48 6 4 years (median 51; range 31 to 63 years). All
had a stable nephrotic syndrome for at least three months
duration. Six of them had membranous glomerulonephritis, one
had steroid-resistant minimal change disease and one had focal
glomerular sclerosis. Patients were prescribed a diet containing
0.8 g protein/kg body wt/day and 100 mmol sodium/day for at least
two weeks before starting the infusion study. Besides diuretics,
none of them received medication, or medication was stopped at
least two weeks before the infusion study. Control studies were
done in seven healthy subjects (3 males, 4 females) who were on
a similar diet as the nephrotic syndrome patients. The mean age
of the control group was 33 6 2 years (median 33; range 25 to 40
years). One day before the infusion study, the subjects collected a
24-hour urine sample that was analyzed for urea, creatinine,
protein and albumin. All patients and volunteers agreed to
participate after signing an informed consent form, in accordance
with the Helsinki Declaration of Human Rights. This study was
approved by the Institutional Ethical Committee for studies in
humans.
MATERIALS
L-[1-13C] valine (isotope mole fraction . 0.99; MassTrace,
Woburn, MA, USA) was dissolved in sterile 0.9% saline and
sterilized through a 0.22 mm filter. All chemicals were obtained
from Riedel de Hae¨n (Seelze, Germany) unless indicated other-
wise. Density solutions were made with KBr in 0.9% NaCl, NaN3
(0.01%) and 1 mmol/liter EDTA.
Methods
Infusion protocol. The infusion protocol has been described in
detail previously [18]. In short, samples were taken to measure the
Evans blue distribution volume, an index for plasma volume [21].
At the baseline (time, t 5 0), a priming dose of 15 mmol/kg
L-[1-13C] valine was administered intravenously over two minutes,
followed by a continuous infusion of 15 mmol/kg/hr L-[1-13C]
valine during six hours. Blood samples (5 ml) were collected into
heparin-containing tubes and into EDTA containing tubes (10
ml). Samples were taken from the contralateral arm at t 5 0, 15,
30, 60, 120, 180, 240, 270, 300, 330 and 360 minutes. Samples were
kept on ice (maximum 1 hr) until plasma was separated by
centrifugation (20 min, 3000 rpm, 4°C). Plasma samples for
isolation of albumin and lipoproteins were immediately stored at
280°C or used directly.
Isolation of free amino acids, albumin and apo B100 from VLDL
and LDL. The isolation of free amino acids from plasma and the
isolation of albumin from heparin plasma, which was based on
differential solubility in absolute ethanol from TCA-precipitated
proteins, was performed as described in detail previously [18].
Lipoproteins were isolated from plasma by sequential ultracen-
trifugation. For the VLDL isolation, 3.0 ml EDTA plasma was
over layered by 2.8 ml of a density solution 1.006 kg/liter and
ultracentrifugated for 20 hours at 40,000 rpm in a 50.3 ti rotor
(Beckman Instruments, Inc., Palo Alto, CA, USA). After tube
slicing, the supernatant was washed by again adding 2.8 ml of the
density solution 1.006 kg/liter to 3 ml supernatant. The VLDL
fraction was obtained after centrifugation and tube slicing again.
Low density lipoprotein was isolated as described elsewhere
[22]. In short, 2.5 ml infranatant of the first run was adjusted with
KBr to a density of 1.24 kg/liter and overlayered by 5 ml of a
density solution 1.12 kg/liter, 2.0 ml of a density solution 1.06
kg/liter and 2.5 ml of a density solution 1.006 kg/liter followed by
ultracentrifugation using a swinging out bucket rotor (SW-40;
Beckman). Density bands were aspirated in 0.5 ml fractions.
Fraction 13 to 21 contained LDL that was free from intermediate
density lipoprotein (IDL) and high density lipoprotein (HDL).
Fractions with Lp(a) contents , 28 mg/liter (detection limit) were
taken. Control experiments were performed and showed that
enrichment in this fraction is a good representation of the total
LDL pool. In two patients who had a detectable Lp(a) concen-
tration in this fraction, the sample was pre-treated with lysine-
sepharose to remove the Lp(a) (, 28 mg/liter).
Apolipoprotein B100 was isolated from the VLDL and LDL
fractions by precipitation with isopropanol as described by Egusa
et al [23]. The precipitate was delipidated with ethanol/ether (3:1)
and thereafter with ether. At each step of the extraction, the
protein-solvent mixture was incubated at 220°C overnight and
was centrifugated at 2000 rpm for 30 minutes. The solvent was
removed by aspiration. After evaporation the remaining ether
fraction, apo B100 was hydrolyzed with 6 N HCl for 24 hours at
110°C [24]. The hydrolysates were supplied to cation-exchange
resin as described previously [18].
Quantification. For quantification of lipids and lipoproteins,
plasma samples were subjected to a single ultracentrifugation step
according to Redgrave, Roberts and West [25]. Plasma, VLDL,
IDL and LDL fractions were assayed for total cholesterol and
triglyceride on a Synchron CX4 (Beckman). The amount of HDL
was measured by precipitating a small aliquot of the bottom
fraction using dextran sulphate-Mg21 [26]. Plasma was assayed for
apo A1 and for apo B100 using a routine nephelometric assay
(Behringwerke AG, Marburg, Germany). For the measurement of
apo B100 in the VLDL and IDL fractions, a nephelometric assay
was used in which the detection limit of the apo B100 assay was 12
mg/liter.
Determination of 13C-valine enrichment. Derivatization of the
isolated amino acids and of the isolated apo B100 was done
according to the method of Husˇek [27]. The N(O,S)-methoxycar-
bonyl methyl ester derivatives of plasma free amino acids and of
apo B100 from VLDL were analyzed by gas chromatography/mass
spectrometry, and the derivatives of apo B100 LDL and of
albumin were analyzed by gas chromatography combustion iso-
tope ratio mass spectrometry as described previously [18].
Calculation/statistics. The apo B100 valine tracer/tracee ratio in
VLDL and LDL were analyzed by mathematical compartmental
modeling (Fig. 1) using SAAM II software [28]. The model
consists of an plasma amino acid pool, a delay compartment that
accounts for the time delay in appearance of VLDL apo B 100
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into plasma, and a series of delipidation compartments represent-
ing VLDL, IDL and LDL pools. In this model k-values represent
the fractional rate at which 13C valine appeared into various apo
B100 lipoprotein pools. Simulations were done using the plasma
valine tracer/tracee ratio as a forcing function to the model, which
allowed an adjustment of the various k-value for an optimal fit to
the VLDL apo B100 and LDL data simultaneously. The k-value
(2,1) represents the fractional rate of synthesis (FSR) of apo B
VLDL. The k-value (0,5) represents the fractional rate of catab-
olism (FCR) of LDL.
Since the measurements were done while apo B100 metabolism
was in steady state, the fractional clearance rate was equal to the
fractional production rate (FCR 5 FSR). The tracer/tracee data
of albumin were analyzed by fitting the data to a multicompart-
mental model consisting of a plasma amino acid pool a delay
element and an albumin pool [29].
The absolute synthesis rate (ASR), which is the amount of
protein synthesized per day, were calculated by multiplying pool
sizes by the corresponding FSR. Pool sizes were calculated by
multiplying the plasma concentrations of albumin, VLDL apo
B100 and LDL apo B100 with the plasma volume measured by
Evans blue. To adjust for different body wts, these quantities are
expressed per kg body wt.
Statistics were performed using t-test. If the normality test or
equal variance test failed a Mann-Whitney Rank sum test was
used. All data are presented as means 6 SEM
Correlations were performed by linear regression analysis.
RESULTS
Clinical and biochemical parameters
As expected, plasma albumin concentration and plasma colloid
oncotic pressure (COP) were significant decreased compared to
the control group (Table 1). Creatinine clearance was also
decreased significantly. Urine urea excretion, as index of protein
intake, was not significantly different from that in the control
subjects. Total triglyceride (TG), VLDL-TG, IDL-TG, total cho-
lesterol (chol), VLDL-chol, IDL-chol and LDL-chol were signif-
icantly elevated in the patients compared to controls (Table 2).
The plasma apo B 100 pool was significantly (P , 0.001) increased
in the nephrotic patients (2.39 6 0.29 g/liter) compared to the
control group (1.03 6 0.09 g/liter), while HDL-chol (Table 2) and
its apolipoprotein A1 (1.45 6 0.15 g/liter vs. 1.26 6 0.08 g/liter)
were not significantly different between nephrotic patients and
controls. Cholesterol levels were increased above the normal
range in all patients and ranged from 7.3 to 15.9 mmol/liter. In
contrast, TG levels ranged from 1.0 to 7.7 mmol/liter. Very low
density lipoprotein apo B100 pool size was increased above the
maximum value found in control subjects in six nephrotic patients,
but was within the normal range in two (No. 7 and 8). Pool sizes
of LDL apo B100 were significantly increased while the pool sizes
of albumin were significantly decreased (Table 3) compared to
normal subjects.
Very low density lipoprotein apolipoprotein B100
Enrichment in plasma free valine reached a plateau after 60
minutes and remained stable during the study, for both patients
and controls (data not shown). The mean coefficient of variation
of plateau was 1.5%. The fraction rate of appearance of 13C valine
in VLDL apo B100 (and thereby the FSR) tended to be lower in
patients than controls (data not shown). Since in steady state FSR
is equal to fractional catabolic rate (FCR), the FCR of VLDL apo
B100 tended to be lower in the entire patient group, although this
value did not reach significance (Table 3 and Fig. 2A). Within the
group of six patients with elevated levels of VLDL apo B100, the
FCR was significantly decreased (13.6 6 3.6%/hr in nephrotic vs.
26.5 6 3.2%/hr in controls, P 5 0.02). Since the VLDL apo B100
pool size was increased more than fivefold in nephrotic patients,
the absolute rate of 13C valine incorporation was greater in the
nephrotic group compared to controls (Table 3 and Fig. 2B). In
four nephrotic patients (No. 2, 3, 5 and 6), the calculated ASR of
VLDL apo B100 was above the highest value found in the control
group, while the remaining patients (No. 1, 4, 7 and 8) had a
calculated ASR of VLDL apo B100 similar to those found in the
control group (Fig. 4B). In the patient group, plasma VLDL apo
B100 concentration correlated inversely with VLDL apo B 100
FCR (Fig. 3A; r2 5 0.708; P 5 0.0088) and bore no relationship
to VLDL apo B 100 ASR (Fig. 3B; r2 5 0.245; P 5 0.21),
suggesting that the expanded VLDL apo B 100 pool size was a
consequence of a decrease in FCR, rather than an increase in
ASR. Furthermore, the FCR of VLDL apo B100 correlated with
plasma VLDL-chol (r2 5 0.716; P 5 0.0081), plasma VLDL-TG
(r2 5 0.784; P 5 0.019) and total plasma triglyceride (r2 5 0.776;
P 5 0.0038). Those nephrotic patients whose triglycerides were
increased all had a decreased FCR of VLDL apo B100, while
those whose triglycerides were within the normal range all had a
FCR of VLDL apo B100 that was not reduced. The VLDL apo
B100 concentration did not correlate with either albumin concen-
tration or urinary albumin secretion (r2 5 0.060; P 5 0.559 and
r2 5 0.071; P 5 0.522, respectively).
Low density lipoprotein apolipoprotein B100
Low density lipoprotein apolipoprotein B100 concentration and
pool size was increased more than twofold in the patient group
Fig. 1. Multicompartmental model for apolipoprotein (apo) B100 metab-
olism. The q1 represents the plasma valine pool (FF 5 forcing function),
d2 is a delay compartment, q3 is the very low density lipoprotein (VLDL)
compartment, q4 is the intermediate density lipoprotein (IDL) compart-
ment, and q5 is the low density lipoprotein (LDL) compartment; s2 and s3
represent sampling points for determination of the tracer/tracee ratio of
the 13C valine in VLDL apo B100 and in LDL apo B100 compartment
respectively. The k-value (2,1) represents the fractional synthesis rate
(FSR) of VLDL apo B100, and k-value (0,5) the fractional catabolic rate
(FCR) for LDL apo B100.
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compared to controls. In contrast to VLDL apo B100, the ASR of
LDL apo B100 was significantly (P , 0.001) increased from a
mean of 6.0 6 0.8 mg/kg/day in the control subjects to 28 6 7
mg/kg/day in 7 nephrotic patients (Fig. 4B). The FCR of LDL
could not be fitted by the model that we used in one patient (No.
4). This finding caused us to consider the possibility of a different
pathway for synthesis of LDL from the usually accepted VLDL-
IDL-LDL route in this patient. The increase in LDL apo B100
synthesis was responsible for the increase in LDL apo B100
concentration and pool size, since the FCR of LDL apo B100
actually tended to be higher in patients than controls, although
this difference did not achieve significance, again due to the wide
range in the individual values (Table 3 and Fig. 4A). The absolute
rate of LDL apo B100 synthesis was greater than the rate of
synthesis of VLDL apo B100 in three of the nephrotic patients
(Table 3), suggesting that the relationship between VLDL and
LDL synthesis is not a direct precursor product relationship, but
instead that at least a component of the LDL pool arises either
directly or by a pathway that does not include VLDL. In the
patient group there was no relationship between the ASR of
albumin and that of apo B100 in LDL or between plasma albumin
concentration and the ASR of LDL apo B100 (r2 5 0.017; P 5
0.779 and r2 5 0.026; P 5 0.728, respectively).
Albumin
In contrast to VLDL apo B100, incorporation of 13C valine into
albumin (FSR) was approximately four times greater in patients
than controls (data not shown). Despite a reduced albumin pool,
the ASR of albumin was significantly (P , 0.0001) increased from
a mean of 72 6 4 mg/kg/day in control subjects to 149 6 20
mg/kg/day in the nephrotic patients (Table 3).
There was no relationship between the ASR of albumin and
that of apo B100 in VLDL (r2 5 0.36; P 5 0.13) in the patient
group. If we excluded the patient (No. 8) with a mild proteinuria
(2.9 g/day) and a similar ASR of albumin to what was observed in
the control group, the relationship becomes worse (r2 5 0.16; P 5
0.38). There was also no relationship between plasma albumin
Table 1. Clinical characteristics of the patients and control subjects
Renal
disease
Age
years Gender
Weight
kg
Body mass
index
kg/m2
Plasma
albumin
g/liter
COP
mm Hg
Creatinine
clearance
ml/min
Urinary
urea
mmol/day
Proteinuria
g/day
Patient no.
1 membr 49 m 82.1 26.5 21.5 10.7 111 261 12.9
2 membr 52 m 86.2 25.2 21.5 11.7 82 146 6.9
3 membr 31 m 73.6 21.7 23.9 11.8 84 254 6.1
4 membr 56 m 92.0 31.8 24.0 11.7 86 332 16.5
5 membr 41 m 85.2 25.2 19.9 9.5 67 388 11.1
6 membr 55 f 96.7 33.9 24.4 12.3 109 421 23.2
7 focal glom 63 f 70.8 25.1 20.6 10.6 62 218 7.4
8 min ch 40 m 68.6 21.4 26.1 15.1 124 382 2.9
Mean 6 SEM 48a 6m/2f 81.9 26.3 22.7b 11.7b 91a 300 10.9b
4 3.6 1.6 0.8 0.6 8 34 2.3
Controls
(N 5 7) 33 3m/4f 77.5 24.3 36.9 24.6 137 348 ,0.1
Mean 6 SEM 2 5.5 1.5 0.8 0.5 9 40 0
Abbreviations are: membr, membranous glomerulonephritis; focal glom, focal glomerulosclerosis; min ch, minimal change disease; COP, colloid
oncolic pressure.
a P , 0.01, b P , 0.0001
Table 2. Levels of plasma lipids, lipoproteins and apolipoproteins A1 and B100 of both groups
TG VLDL-TG IDL-TG Chol VLDL-chol IDL-chol LDL-chol HDL-chol Apo A1 Apo B100
mmol/L g/liter
Patient No.
1 7.7 4.3 0.4 13.9 2.1 2.0 9.0 0.9 1.70 2.80
2 6.0 3.6 0.5 13.1 3.1 2.3 7.1 0.7 1.12 2.29
3 4.0 2.4 0.4 15.6 2.0 3.2 9.7 0.7 1.17 3.25
4 5.6 2.8 0.3 7.3 1.4 0.7 4.7 0.5 0.92 1.57
5 2.4 0.9 0.5 8.4 0.9 2.5 4.0 1.0 1.18 1.64
6 3.7 1.2 0.6 15.9 1.9 4.2 8.4 1.4 2.18 3.36
7 2.4 0.3 0.4 15.3 0.4 4.0 10.1 0.9 1.63 2.94
8 1.0 0.04 0.1 7.3 0.05 1.6 4.2 1.4 1.67 1.30
Mean 6 SEM 4.1b 1.9a 0.4b 12.1c 1.5a 2.6b 7.1c 0.9 1.45 2.39c
0.8 0.6 0.1 1.3 0.4 0.4 0.9 0.1 0.15 0.29
Controls
(N 5 7) 1.3 0.3 0.14 5.2 0.3 0.9 3.0 1.1 1.26 1.03
Mean 6 SEM 0.1 0.1 0.02 0.3 0.1 0.1 0.2 0.1 0.08 0.09
Abbreviations are in the Appendix.
a P , 0.05, b P , 0.01, c P , 0.001 significantly different from control group
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concentration and the ASR of VLDL apo B100 (r2 5 0.20; P 5
0.26).
DISCUSSION
The present study showed that while some patients had in-
creased secretion of VLDL apo B 100, hypertriglyceridemia in the
nephrotic patients was mainly a result of a defect in VLDL apo
B100 catabolism. The increase in absolute synthesis rate was
incidental to increased plasma levels of VLDL, VLDL apo B100
or to increased levels of triglycerides. Synthesis of VLDL apo
B100 was not significantly related to albumin synthesis or plasma
albumin concentration. The LDL apo B100 pool was increased in
all patients, and in contrast to the VLDL apo B100 pool, the FCR
was not decreased. The ASR of LDL apo B100 was significantly
increased in all patients. Indeed, the fractional turnover rate for
LDL apo B100 was actually increased in the majority of our
patients.
A defect in VLDL catabolism was also suggested in two small
studies both performed in four nephrotic patients [3, 5]. Also, the
observation by Warwick et al [2] suggested that a catabolic defect
of VLDL apo B100 plays an important role in nephrotic dyslipi-
demia. The current study validates these findings and correlates
impaired catabolism directly to hypertriglyceridemia in patients
with a nephrotic syndrome. Physical and/or chemical changes of
VLDL particles [30] as well as a decrease in LPL activity [31, 32]
have been suggested as causes for impaired catabolism of VLDL.
However, Davies et al showed a normal clearance of VLDL in
hereditary analbumenic rats, which have a decreased LPL activity,
Fig. 2. Box plots showing the fractional
catabolic rate (A; FCR, %/hr) and the absolute
synthesis rate (B; ASR, mg/kg/day) of very low
density lipoprotein (VLDL) apolipoprotein
(apo) B100 in both patients and controls.
Shown are the mean (black line), median
(dotted line) and range (vertical bars). *P ,
0.05.
Table 3. Kinetics of apo B100 and albumin
Apo B100 from VLDL Apo B100 from LDL Albumin
FCR
%/hr
Pool size
mg
ASR
mg/kg/day
FCR
%/hr
Pool size
mg
ASR
mg/kg/day
Pool size
g
ASR
mg/kg/day
Patient no.
1 5.9 1327 23 1.3 3659 14 69 158
2 9.5 1852 49 5.8 3172 50 87 179
3 12.3 822 33 1.3 5572 23 81 241
4 5.5 648 9 — 2395 — 75 126
5 28.2 490 39 1.1 3320 11 75 111
6 19.9 967 48 1.2 6078 18 94 194
7 47.2 170 27 3.2 4920 53 58 107
8 47.0 32 5 3.3 2397 28 79 71
Mean 6 SEM 21.9 789a 29a 2.4 3939b 28c 77d 149b
6.1 212 6 0.7 500 7 4 20
Controls
9 18.8 138 8 1.1 1785 6 127 53
10 32.9 250 28 1.1 2070 8 118 70
11 22.7 143 9 1.0 2296 6 124 88
12 28.1 208 14 1.3 1966 6 125 63
13 37.7 170 23 1.9 1378 10 101 81
14 31.4 83 9 0.7 1343 3 109 77
15 13.8 38 2 1.0 961 4 93 71
Mean 6 SEM 26.5 147 13 1.1 1686 6 114 72
3.2 29 4 0.1 179 1 5 4
The parameters for VLDL and LDL apo B100 were estimated using a multicompartmental model as shown in Figure 1. The FCR of apo B100 LDL
could not be established in patient no. 4. Abbreviations are in the Appendix.
a P , 0.05, b P , 0.01, c P , 0.001, d P , 0.0001 significantly different from the control group
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while the clearance of VLDL was significantly reduced when the
nephrotic syndrome is imposed [33]. These observations suggest
that a decrease in LPL activity may be less important in the
nephrotic syndrome. As the IDL pool (the formation of which is
also dependent upon LPL activity) is increased several times in
this study as well as in the study of Aguilar Salinas et al [5], it is
tempting to speculate that there is a decrease in the direct
clearance of VLDL apo B100 in the nephrotic patients. Recently,
a VLDL receptor was described that specifically bound apo
E-containing lipoproteins such as VLDL and IDL, and which was
expressed in peripheral tissue including heart and skeletal muscle,
adipose tissue, kidney and brain but not in liver [34]. A decrease
in this specific receptor may result in a reduced-mediated uptake
of plasma VLDL and hence a reduced clearance of these lipopro-
teins from the plasma. This hypothesis is further supported by a
recent study of Liang and Vaziri, who showed that the VLDL
receptor was reduced in heart and skeletal muscle in puromycin
induced nephrotic rats and that receptor protein was inversely
related to plasma VLDL and triglyceride concentrations [35].
All of the patients in our study had an increased cholesterol
concentration in all lipoprotein fractions containing apo B100.
The increased LDL apo B100 concentration in these patients
could not be correlated statistically to either the FCR of LDL apo
B100 nor the ASR of LDL apo B100. However, in all patients the
ASR of LDL apo B100 was significantly higher compared to the
control group. Furthermore, the FCR of LDL apo B100 tended to
be higher in patients compared to controls. One could postulate
that this increased apo B synthesis reflects apo B100 input from
the VLDL delipidation pathway. However, synthesis of LDL apo
B100 was larger than synthesis of in VLDL apo B100 in some
patients (No. 7 and 8), suggesting a direct synthesis of LDL
bypassing VLDL-delipidation. If so, this shunt pathway may also
exist in other patients, as the LDL apo B100 synthesis that is
measured is derived both from LDL secreted through VLDL as
well as possible alternative pathways. It is not possible to establish
what fraction of the LDL apo B100 pool is derived from VLDL
and what fraction of that pool is a consequence of the proposed
alternate pathway of synthesis, since total LDL apo B100 synthesis
Fig. 3. Relationship between plasma very low
density lipoprotein (VLDL) apolipoprotein
(apo) B100 (mg/liter) and the fractional
catabolic rate (FCR) of apo B100 (%/hr) in
nephrotic patients (A; r2 5 0.708, P 5 0.0088).
The 95% confidence limits of the whole group
are shown on either side of the regression line
(N 5 8). Relationship between plasma VLDL
apo B100 (mg/liter) and the absolute synthesis
rate (ASR) of VLDL apo B100 (mg/kg/day) for
nephrotic patients (B; r2 5 0.25, P 5 0.21; N 5
8).
Fig. 4. Box plots showing the fractional
catabolic rate (FCR %/hr; A) and the absolute
synthesis rate (ASR) of low density lipoprotein
(LDL) apolipoprotein (apo) B100 (mg/kg/day;
B) in both patients and controls. Shown are the
mean (black line), median (dotted line) and
range (vertical bars) (*P 5 0.001).
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rate is a sum of the two pathways. The existence of direct LDL
secretion and normal LDL catabolism is also suggested from the
data from Vega and Grundy [3] and Aguilar Salinas et al [5]. By
contrast, Warwick et al [2, 4] in two different studies showed a
decreased catabolic rate of LDL as the main mechanism for the
increased LDL pool. Notably, the latter study used exogenously
labeled lipoproteins that may be subject to alternative catabolism.
Our present data show no clear relationship between the ASR
of VLDL apo B100 and the ASR of albumin in nephrotic patients
(r2 5 0.36; P 5 0.13). Although more studies need be done in
order to exclude a definite relationship, the lack of correlation is
strikingly different from that between fibrinogen synthesis and
albumin synthesis reported previously by us [18]. In addition,
regulation of hepatic apo B100 secretion does not appear to be
modulated transcriptionally, but rather translationally or post-
translationally [36], while albumin is transcriptionally regulated
[37]. We also found no relationship between apo B100 secretion in
LDL and albumin synthesis in the nephrotic patient (r2 5 0.02;
P 5 0.78). Since the LDL apo B100 pool is at least in part derived
from VLDL, it is possible that direct synthesis and secretion of
LDL may parallel that of albumin, but we have not tested this
hypothesis directly since we cannot distinguish between sources of
the LDL pool secreted through VLDL and sources secreted by
alternate pathway(s). Since it was suggested that a low COP [10,
20], albumin or proteinuria [10, 38, 39] may play a role in apo
B100 metabolism, we tested these relationships, but none of them
achieved statistical significance.
The disturbances in lipoprotein profile in the nephrotic syn-
drome may not only be relevant to the increased risk of coronary
atherosclerosis in these patients, but may also play a role in the
progression of renal disease [40–44]. Our data indicate that the
therapies aimed at induction of the VLDL receptor or suppres-
sion of secretion of VLDL (such as microsomal triglyceride
transfer protein inhibitors or the new HMG-CoA reductase
inhibitor, atorvastatine) could be more successful than current
standard therapy to achieve full restoration of dyslipidemia in
these patients.
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APPENDIX
Abbreviations used in this article are: apo, apolipoprotein; ASR,
absolute synthesis rate; chol, cholesterol; COP, colloid oncotic pressure;
FCR, fractional catabolic rate; FSR, fractional rate of synthesis; HDL,
high density lipoprotein; IDL, intermediate density lipoprotein; LDL, low
density lipoprotein, NS, nephrotic syndrome; TG, triglyceride; VLDL,
very low density lipoprotein.
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